Browse Trials
In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.
Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.
Currently viewing trials
(Last updated: June 14, 2021)
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
NEAREST SITE: 339 miles
UCLA David Geffen
Santa Monica,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: II
NCT ID: NCT04596150
CX-2009 Alone or with the Experimental PD-L1 Inhibitor CX-072 for Advanced HER2 Negative Breast Cancer
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination With CX-072 in Advanced Triple-Negative Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Hormone positive, HER2 negative</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009, by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Triple negative, CD166 expression</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009, by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Triple negative, PD-L1 positive</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009, by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">CX-072, by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009 is an experimental therapy that targets the protein CD166 on cancer cells to deliver the anti-cancer drug DM4.</li> <li class="seamTextUnorderedListItem">CX-072 is a type of an experimental immunotherapy called a PD-L1 inhibitor. </li> <li class="seamTextUnorderedListItem">Targets or mutations: CD166, PD-L1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04596150' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cytomx.com/pipeline/' target='_blank'>CytomX Therapeutics Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.526' target='_blank'>Journal Abstract: CX-2009, a CD166-Directed Probody Drug Conjugate</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/cx-072/' target='_blank'>Immunotherapy-Oncology News: CX-072</a> </li></ul>
